- PROFESSOR | Neurosurgery
- PROFESSOR | Oncological Sciences
- PROFESSOR | Medicine
- Hospital Affiliation
- The Mount Sinai Hospital
- Mount Sinai Doctors Faculty Practice 212-241-0933212-241-0933
Dr. Post began his academic career in 1976 as an Instructor of Neurosurgery at Tufts University School of Medicine.He left Tufts four years later as Associate Professor to join the faculty at Columbia University College of Physicians and Surgeons as an Associate Professor. Named Vice-Chairman of that Department in 1984, Dr. Post was promoted to Professor in 1987. In 1991 he moved to Mount Sinai. He has been President of the New York Neurosurgical Society and the New York State Neurosurgical Society and is presently on the Editorial Board of Neurosurgery.
Dr. Post is internationally known for his work and results treating pituitary and parasellar tumors, as well as cerebello-pontine angle tumors, particularly acoustic neuroma with hearing preservation. He is a member of the Endocrine Society and was a m ember of the Board of Directors of the Pituitary Society. In 2009 he received the award as Endocrinologist of the Year from the Department of Medicine, Division of Endocrinology at Mount Sinai.
- Acoustic Neuroma
- Arnold-Chiari Syndrome
- Brain Tumor And Brain Cancer
- Cushing's Syndrome
- Glioblastoma Multiforme
- Hearing Loss
- Pituitary Adenoma
MD, NYU Medical Center
Bellevue Hospital Center
Endocrinologist of the Year 2009
The Hilda and J Lester Gabrilove MD Division of Endocrinology Diabetes and Bone Diseases
America's Top Doctors
Castle Connolly Guide
Best Doctors in the New York Metro Area
Castle Connolly Guide
Award for dedication to mentoring and support of women in neurosurgery
Friends of WINS
Faculty teaching award from class of 1979
Tufts University School of Medicine
Alpha Omega Alpha Society
Long term clinical outcome studies of acoustic neuroma and pituitary tumor patients.
Laboratory studies involving the molecular biology of pituitary tumors.
Does Surgical Debulking Pituitary Adenomas Improve Responsiveness to Octreotide LAR in the treatment of acromegaly: An investigator-initated study
The purpose of this study is to see whether pituitary surgery (called debulking) improves the response to a medication called Sandostatin LAR in subjects with acromegaly. Sandostatin LAR (also call Octreotide LAR) is approved by the Food and Drug Administration (FDA) for the pur...
Molecular Analysis of Pituitary Tumors
The purpose of this study is to examine human pituitary tumor specimens to better understand the formation of pituitary tumors. Patients may qualify for participation in the study if they have a pituitary tumor that they have elected to remove surgically.
Geer EB, Shen W, Gallagher D, Punyanitya M, Looker HC, Post KD, Freda PU. MRI Assessment of Lean and Adipose Tissue Distribution in Female Patients with Cushing's Disease. Clin Endocrinol (Oxf). 2010 June;: Epub ahead.
Gandhi CD, Christiano LD, Eloy JA, Prestigiacomo CJ, Post KD. The historical evolution of transsphenoidal surgery: facilitation by technological advances.. Neurosurg Focus 2009 Sept; 27(3): E8.
Reid TJ, Post KD, Bruce JN, Nabi Kanibir M, Reyes-Vidal CM, Freda PU. Features at diagnosis of 324 patients with acromegaly did not changes from 1981-2006: Acromegaly remains under-recognized and under-diagnosed. . Clinical Endocrinol 2009 May; 72(2): 203-208.
Jehle S, Walsh J, Freda PU, Post KD. Selective use of bilateral inferior petrosal sinus sampling in patients with adrenocorticotropin dependent Cushing's syndrome prior to transsphenoidal surgery.. J. Clin Endocrinol Metab 2008 Sept; 93(12): 4624-4632.
Neurologic complications of inferior petrosal sinus sampling. AJNR 2008 Apr; 29(4): 760-765.
Freda PU, Chung WK, Matsuoka N, Walsh JP, Kanibir MN, Kleinman G, Wang Y, Bruce JN, Post KD. Analysis of GNAS mutations in 60 GH secreting pituitary tumors: correlation with clinical and pathological characteristics and surgical outcome based on highly sensitive GH and IGF-1 criteria for remission.. Pituitary 2007; 10(3): 275-282.
Tamler R, Lee AK, Lewis MS, Post KD. It's all in the head: insomnia and anxiety caused by thyrotropin-secreting pituitary adenoma.. Thyroid 2006 Mar; 16(3): 317-318.
Freda PU, Chung WK, Matsuoka N, Walsh JP, Kanibir MN, Kleinman G, Wang Y, Bruce JN, Post KD. Analysis of GNAS mutations in 60 GH secreting pituitary tumors: correlation with clinical and pathological characteristics and surgical outcome based on highly sensitive GH and IGF-1 criteria for remission. Pituitary 2007; 10(3): 275-282.
Puder JJ, Nilaver S, Post KD, Freda PU. Relationship between disease-related morbidity and biochemical markers in patients with acromegaly. JCEM 2005 Apr; 90(4): 1972-1978.
Benveniste RJ, King WA, Walsh J, Lee JC, Delman B, Post KD, . Repeated transsphenoidal surgery to treat recurrent or residual pituitary adenoma. J Neurosurg 2005 Jun; 102(6): 1004-1012.
Shrivastava RK, Epstein FJ, Perin NI, Post KD, Jallo GI. Intramedullary spinal cord tumors in patients older than 50 years of age: management and outcome analysis. J Neurosurg Spine 2005 Mar; 2(3): 249-255.
Betchen SA, Walsh J, Post KD. Long-term hearing preservation after acoustic neuroma surgery. J Neurosurg 2005 Jan; 102: 6-9.
Benveniste RJ, King WA, Walsh J, Lee JC, Naidich TP, Post KD. Surgery for Rathke's cleft cysts: Technical considerations and outcomes. J Neurosurg 2004 Oct; 101(4): 577-584.
Freda PU, Nuruzzaman AT, Reyes CM, Sundeen RE, Post KD. Significance of abnormal nadir GH levels after oral glucose in postoperative patients with acromegaly in remission with normal IGF-1 levels. JCEM 2004 Feb; 89(2): 495-500.
Freda PU, Wardlaw SL, Post KD. Long-term endocrinologic follow-up of 115 patients after transsphenopidal surgery for acromegaly. J Neurosurgery 1998; 89: 353-358.
Betchen SA, Walsh J, Post KD. Self-assessed quality of life after acoustic neuroma surgery. J Neurosurg 2003 Nov; 99(5): 818-823.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Post did not report having any of the following types of financial relationships with industry during 2016 and/or 2017: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.